Global Tuberculosis Report -- 2012.pdf

● The 14 countries not included in the list of 22 HBCsbut that are part of the list of the 27 high MDR-TBburden countries are all European countries. Of these14 countries, six are upper middle-income countriesand one is a high-income country (Estonia). Amongthe seven low- and lower middle-income countries,available funding from domestic sources appears to besufficient, although some rationalization in the use ofhospital care may be required.● The 17 HBCs outside BRICS require donor funding ofabout US$ 0.3–0.5 billion per year to reach Global Plantargets for implementing DOTS and scaling up diagnosisand treatment for MDR-TB. This amount could belowered if reductions in the price of second-line anti-TB drugs needed for treatment of MDR-TB could beachieved.● Low-income countries require donor funding of aboutUS$ 0.2–0.3 billion per year to reach Global Plan targetsfor implementing DOTS and scaling up diagnosisand treatment for MDR-TB, of which US$ 0.1–0.2 billionper year is in countries outside HBCs.In addition to the funding needs for DOTS and MDR-TBset out in the Global Plan, additional investments will beneeded for the scale-up of new rapid molecular diagnostics.Further details about these diagnostics are providedin Chapter 6.Overall, these observations suggest that internationaldonor funding of up to US$ 1 billion per year is neededfor diagnosis and treatment of TB and MDR-TB in lowandmiddle-income countries 2013–2015 to close fundinggaps. It is anticipated that most of the funding requiredfor TB/HIV interventions will also need to come frominternational donor sources.GLOBAL TUBERCULOSIS REPORT 2012 65